Biosciences announced the presentation of a new post-hoc analysis from the Phase 3, open-label KINECT 4 study, demonstrating that patients treated continuously for 48 weeks with the 40 mg dose of once ...
TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced ...
GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in itching that began after two weeks and persisted through the 24-week primary ...
In a Phase II trial, LEVI-04 demonstrated a significant, dose-dependent reduction in bone marrow lesions (BML) compared with placebo in patients ...
Endeavor BioMedicines Announces Publication of Positive Data from Phase 2a Trial in The Lancet Respiratory Medicine Evaluating taladegib (ENV-101) in Individuals with Idiopathic Pulmonary Fibrosis ...
During AANEM, Dr. Pushpa Narayanaswami, MD from Harvard Medical School presented the successful Phase 2 MaGic trial data for the first time at a medical conference. In addition, during a Virtual ...
The novel serotonin norepinephrine reuptake inhibitor (SNRI) ammoxetine may effectively treat major depressive disorder (MDD) while avoiding some side effects common to other antidepressants, new ...
Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy was featured at the 2025 International Congress of ...
A single dose of a synthetic form of psilocybin known as COMP360 (Compass Pathways) is both statistically significant and clinically meaningful in reducing treatment-resistant depression (TRD) in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback